Seehra Jasbir
SEC insider (Form 3/4/5 filer). CIK 0001732369. CHIEF EXECUTIVE OFFICER at Keros Therapeutics, Inc. (KROS). 7 reported Form 4/5 transactions since Sep 2024; latest on Apr 2, 2026. Located in LEXINGTON, MA.
Companies Seehra Jasbir has filed insider reports for
- Keros Therapeutics, Inc. (KROS): Director, Officer, CHIEF EXECUTIVE OFFICER
Seehra Jasbir
CIK: 0001732369
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Keros Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Apr 2, 2026KROS
Keros Therapeutics, Inc.
ExerciseDirect55K shares at avg. $0.30$17K - Feb 24, 2026KROS
Keros Therapeutics, Inc.
AwardDirectEmployee Stock Option (Right to Buy)
217K shares- - Feb 24, 2026KROS
Keros Therapeutics, Inc.
AwardDirectEmployee Stock Option (right to buy)
100K shares- - Feb 19, 2026KROS
Keros Therapeutics, Inc.
SaleDirect7K shares at avg. $16.17$113K - Jan 7, 2026KROS
Keros Therapeutics, Inc.
AwardDirectEmployee Stock Option (right to buy)
62.5K shares- - Sep 3, 2025KROS
Keros Therapeutics, Inc.
AwardDirect90.5K shares- - Apr 4, 2025KROS
Keros Therapeutics, Inc.
ExerciseDirect49.4K shares at avg. $0.30$15K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 2, 2026 | KROS Keros Therapeutics, Inc. | Exercise | 55,000 | $0.30 | $16,500 | Direct |
| Feb 24, 2026 | KROS Keros Therapeutics, Inc. | Award Employee Stock Option (Right to Buy) | 217,000 | - | - | Direct |
| Feb 24, 2026 | KROS Keros Therapeutics, Inc. | Award Employee Stock Option (right to buy) | 100,000 | - | - | Direct |
| Feb 19, 2026 | KROS Keros Therapeutics, Inc. | Sale | 7,015 | $16.17 | $113,433 | Direct |
| Jan 7, 2026 | KROS Keros Therapeutics, Inc. | Award Employee Stock Option (right to buy) | 62,500 | - | - | Direct |
| Sep 3, 2025 | KROS Keros Therapeutics, Inc. | Award | 90,500 | - | - | Direct |
| Apr 4, 2025 | KROS Keros Therapeutics, Inc. | Exercise | 49,367 | $0.30 | $14,810 | Direct |
1-7 of 7 transactions